Source: EP Vantage (originally posted 30 Sept 2011) Improved Gardasil? As the global debate about the cost effectiveness – and in some places ethics – of human papilloma virus (HPV) vaccines rumbles on, Merck & Co has been quietly working away on a 21,000 patient phase III program for an improved version of its blockbuster vaccine Gardasil. Relatively […]
A Study of V503 in Females 12-26 Years of Age Who Have Previously Received GARDASIL™
V503 is a multi-valent HPV vaccine still under development by Merck & Co.